Phathom Pharmaceuticals (PHAT) News Today $9.04 +0.07 (+0.78%) Closing price 04:00 PM EasternExtended Trading$9.10 +0.06 (+0.66%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.4% Higher - Should You Buy?Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 6.4% - Time to Buy?June 11 at 3:18 PM | marketbeat.comTiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: BuyJune 10 at 10:08 AM | seekingalpha.comCraig Hallum Raises Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $17.00June 10 at 1:51 AM | americanbankingnews.comPhathom Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:PHAT)June 10 at 1:03 AM | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 9.7% - Here's What HappenedPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 9.7% - Here's What HappenedJune 9 at 2:39 PM | marketbeat.comPhathom: Share Price Surge On Patent News May Not Stop The Rot For LongJune 9 at 12:37 PM | seekingalpha.comTraders Purchase High Volume of Call Options on Phathom Pharmaceuticals (NASDAQ:PHAT)Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) was the target of some unusual options trading activity on Monday. Investors acquired 2,377 call options on the company. This represents an increase of 134% compared to the average daily volume of 1,017 call options.June 9 at 11:32 AM | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given New $17.00 Price Target at Craig HallumCraig Hallum raised their price target on shares of Phathom Pharmaceuticals from $12.00 to $17.00 and gave the stock a "buy" rating in a research report on Monday.June 9 at 11:17 AM | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Phathom Pharmaceuticals in a research note on Monday.June 9 at 8:19 AM | marketbeat.comPhathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032June 9 at 12:40 AM | finanznachrichten.deStifel analysts affirm Buy rating for Phathom Pharmaceuticals stockJune 7, 2025 | investing.comWellington Management Group LLP Sells 37,388 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Wellington Management Group LLP reduced its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 21.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 135,995 shares of the company's stock after sellinJune 7, 2025 | marketbeat.comPhathom Pharmaceuticals shares soar on FDA exclusivity grantJune 6, 2025 | uk.finance.yahoo.comPhathom Pharmaceuticals price target raised to $29 from $23 at Cantor FitzgeraldJune 6, 2025 | msn.comPhathom surges 125% after FDA grants petition on Voquezna exclusivityJune 6, 2025 | msn.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday.June 6, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Sees Unusually-High Trading Volume - Here's WhyPhathom Pharmaceuticals (NASDAQ:PHAT) Sees Large Volume Increase - Here's What HappenedJune 6, 2025 | marketbeat.comPhathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032June 6, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Acquired by Bank of America Corp DEBank of America Corp DE lifted its stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 60.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 166,505 shares of the company's stock after buying an addiJune 6, 2025 | marketbeat.comTwo Sigma Advisers LP Invests $1.09 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Two Sigma Advisers LP bought a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 133,700 shares of the company's stock, valued at approximately $1,June 1, 2025 | marketbeat.comTwo Sigma Investments LP Has $3.95 Million Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Two Sigma Investments LP lifted its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 215.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 485,790 shares of the company's stock after acquirMay 30, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Buy" from AnalystsShares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has giMay 26, 2025 | marketbeat.comNorthern Trust Corp Has $3.23 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Northern Trust Corp increased its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 24.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 397,964 shares of the company's stock after bMay 26, 2025 | marketbeat.comJames N. Topper Buys 3,780 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) Director James N. Topper purchased 3,780 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The shares were bought at an average cost of $3.86 per share, for a total transaction of $14,590.80. Following the completion of the acquisition, the director now directly owns 59,403 shares in the company, valued at $229,295.58. The trade was a 6.80% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.May 25, 2025 | marketbeat.comWoodline Partners LP Cuts Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Woodline Partners LP lessened its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 61.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,001,692 shares of thMay 25, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director James N. Topper Acquires 3,780 SharesMay 24, 2025 | insidertrades.comTang Capital Management LLC Takes $4.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Tang Capital Management LLC acquired a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 500,000 shares of the company's stock, valued at approximately $4,0May 20, 2025 | marketbeat.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 15, 2025 | globenewswire.comCubist Systematic Strategies LLC Makes New Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Cubist Systematic Strategies LLC bought a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 282,553 shares of the company's stock, valued at approximately $2,2May 14, 2025 | marketbeat.comPhathom Pharmaceuticals surges 50% following large insider purchaseMay 9, 2025 | msn.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires $13,000.00 in StockMay 9, 2025 | insidertrades.comAvidity Partners Management LP Lowers Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Avidity Partners Management LP decreased its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 23.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,390,100 shares of tMay 6, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price TargetMay 4, 2025 | finance.yahoo.comPhathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $20.00 at HC WainwrightHC Wainwright decreased their target price on Phathom Pharmaceuticals from $28.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday.May 4, 2025 | marketbeat.comMarshall Wace LLP Takes $796,000 Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Marshall Wace LLP acquired a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 98,068 shares of the company's stock, valuMay 4, 2025 | marketbeat.comOracle Investment Management Inc. Reduces Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Oracle Investment Management Inc. cut its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 84.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 145,064 shares of the company's stock after sellingMay 3, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call TranscriptMay 3, 2025 | seekingalpha.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call TranscriptMay 2, 2025 | msn.comPhathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...May 2, 2025 | finance.yahoo.comRetail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 MissMay 2, 2025 | msn.comPhathom Pharmaceuticals Reports Q1 2025 Financial ResultsMay 2, 2025 | tipranks.comPhathom pharmaceuticals outlines VOQUEZNA expansion targets and cost-saving measures for profitability by 2026May 2, 2025 | msn.comPhathom Pharmaceuticals Eyes Profitability Amid GrowthMay 1, 2025 | tipranks.comPhathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 1, 2025 | seekingalpha.comPhathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 1, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Buy" from BrokeragesShares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, fiveMay 1, 2025 | marketbeat.com3PHAT : Insights Ahead: Phathom Pharmaceuticals's Quarterly EarningsMay 1, 2025 | benzinga.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Lowered by Gilder Gagnon Howe & Co. LLCGilder Gagnon Howe & Co. LLC trimmed its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 97.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,610 shares of the company's stock after selling 1,581,273 sharesApril 30, 2025 | marketbeat.com455,837 Shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Purchased by Raymond James Financial Inc.Raymond James Financial Inc. purchased a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 455,837 shares of the company's stock, valApril 29, 2025 | marketbeat.com Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.541.01▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼274▲PHAT Articles Average Week Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Apellis Pharmaceuticals News Xenon Pharmaceuticals News Amneal Pharmaceuticals News Mirum Pharmaceuticals News Arrowhead Pharmaceuticals News NewAmsterdam Pharma News Recursion Pharmaceuticals News Kiniksa Pharmaceuticals News Vericel News Denali Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHAT Stock Free PHAT Stock Alerts